



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/00		A2	(11) International Publication Number: WO 99/66914 (43) International Publication Date: 29 December 1999 (29.12.99)		
(21) International Application Number: PCT/IT99/00175 (22) International Filing Date: 17 June 1999 (17.06.99)		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).			
(30) Priority Data: RM98A000425 25 June 1998 (25.06.98) IT					
(71) Applicant (for all designated States except US): SIGMA-TAU HEALTHSCIENCE S.P.A. [IT/IT]; Via Treviso, 4, I-00040 Pomezia (IT).					
(72) Inventor; and (75) Inventor/Applicant (for US only): CAVAZZA, Claudio [IT/IT]; Piazza Campitelli, 2, I-00186 Roma (IT).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).			
(74) Agents: CAVATTIONI, Fabio et al.; Cavattioni – Raimondi, Viale dei Parioli, 160, I-00197 Roma (IT).		<p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>			
(54) Title: NEUROPROTECTIVE COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF NERVOUS AND BEHAVIOURAL ALTERATIONS DUE TO ANXIETY STATES OR DEPRESSION					
(57) Abstract					
<p>A composition is disclosed for the prevention and/or therapeutic treatment of nervous and behavioural alterations due to anxiety states or depression that may take the form of a dietary supplement, dietetic support or of an actual medicine which comprises as characterizing active ingredients aceyl L-carnitine and hypericin.</p>					

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression

The present invention relates to a composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression.

Accordingly the composition may take the form and exert the action of a dietary supplement or of an actual medicine, depending upon the support or preventive action, or the strictly therapeutic action, which the composition is intended to exert in relation to the particular individuals it is to be used in.

Particularly the present invention relates to a composition which comprises in combination:

- (a) acetyl L-carnitine or a pharmacologically acceptable salt thereof, optionally in combination with at least another "carnitine" where for "carnitine" is intended L-carnitine or an alkanoyl L-carnitine selected from the group comprising propionyl-L-carnitine, valeryl L-carnitine, isovaleryl L-carnitine or their pharmacologically acceptable salts; and
- (b) 1,3,4,6,8,13-hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione (hypericin) or Hypericum extract (*Hypericum perforatum* L., "Saint-John's-wort") comprising at least 0.3% by weight of hypericin.

The new composition can be orally, parenterally, rectally or transdermally administered both to humans and animals, as a pharmaceutical composition, dietary supplement or phytotherapy preparation.

The use of *Hypericum* extracts was already well known to popular medicine owing to its ability to combat a series of pathological alterations including both conditions such as depression, anxiety,

insomnia, neuralgia, migraine, dyspepsia and sciatica, and inflammatory and scarring processes.

Hypericum contains numerous active components in its extracts, the most interesting of which are the naphthodianthrones, flavonoids, phloroglucinols, xanthones and a number of essential oils.

The main naphthodianthrones are hypericin, pseudohypericin and emodianthrone.

The main flavonoids are proanthocyanidins consisting in various trimers and tetramers or polymers of catechin and epicatechin.

The phloroglucinols include prenylated derivatives of phloroglucinol, hyperperin and perforin.

In addition to caffeic acid, coumaric acid and ferulic acid, essential oils are also present, consisting mainly in monoterpenes and sesquiterpenes.

Of all the components, hypericin is the one which more than any other has proved most interesting owing to its easy characterisation and its specificity of action.

It is, in fact, mainly to hypericin that the acknowledged anti-depressant, anxiolytic, scar-healing and antiviral effects of Hypericum extracts are to be attributed.

Recent research has demonstrated that hypericin inhibits monoaminoxidases and cerebral serotonin reuptake, and reduces the expression of cytokines, particularly interleukin-6.

Many types of activity are exerted by the carnitines, which are generally capable of activating the processes necessary for ATP synthesis via β -oxidation of fatty acids as well as of promoting

stabilisation of the cell membranes against oxidative processes of both the cardiovascular and cerebral systems.

Acetyl L-carnitine improves behavioural parameters in the rat and electro-encephalographic abnormalities in elderly patients.

Neuroregeneration can also be improved by the administration of carnitines.

Surprisingly, it has now been demonstrated that a composition containing as its characterising components a combination of:

- (a) acetyl L-carnitine or a pharmacologically acceptable salt thereof; and
- (b) hypericin,

is extremely effective in the prevention and/or therapeutic treatment of nervous disorders related to states of anxiety or depression, as a result of the potent synergistic effect produced by its components.

It has also been found that, advantageously, component (a) may further comprise a "carnitine" selected from the group consisting of L-carnitine, propionyl L-carnitine, valeryl L-carnitine, isovaleryl L-carnitine or their pharmacologically acceptable salts or mixtures thereof, and that component (b) may consist of a hypericum (*Hypericum perforatum* L., "Saint-John's-wort") extract containing at least 0.3% by weight of hypericin.

The (a):(b) weight-to-weight ratio ranges from 1:0.01 to 1:1. When component (b) of the composition is present in the form of an extract of vegetable products containing it, these vegetable products include the flowers, buds and apical leaves of the Hypericum plant.

Toxicology tests

In these tests, the administration of high doses of either the carnitine mixture, or of acetyl L-carnitine, or of the Hypericum extract or

hypericin alone or of a combination of the aforesaid components proved to be well tolerated both after single-dose administration and after prolonged administration for thirty days. Tests conducted both in rats and mice, with the oral administration of doses of 2 g/kg of carnitine mixture (consisting of a combination of L-carnitine + acetyl L-carnitine + propionyl L-carnitine + isovaleryl L-carnitine present in the same weight ratio to one another), or of 2 g/kg of acetyl L-carnitine, or 1 g/kg of Hypericum extract containing approximately 0.3% of hypericin, or of 3 mg/kg of hypericin, or various combinations of these products, i.e. 1 g/kg of carnitine mixture or 1 g/kg of acetyl L-carnitine in combination with 600 mg/kg of Hypericum extract or 1 mg/kg of hypericin, have provided evidence of a lack of toxic effects or mortality in the animals thus treated. Even the prolonged administration for thirty days consecutively of doses of 500 mg/kg of carnitine mixture or of acetyl L-carnitine in combination with 500 mg/kg of Hypericum extract or 1 mg/kg of hypericin, was well tolerated and devoid of toxic effects. At the end of this treatment, no abnormal blood chemistry parameters were detectable and the histology examination performed on the main organs (heart, lungs, liver, kidneys) failed to reveal any damaging effects of the combination of products administered.

Protective action against abnormal brain serotonin concentrations induced by neurotoxic substances

Since changes in concentration of cerebral biogenic amines regulate both excitatory and depressive emotional behaviour states, it was decided, in view of the above-mentioned action of hypericin and Hypericum extracts at catecholamine and particularly serotoninergic receptor level and on the reuptake of serotonin itself, to evaluate changes in cerebral concentrations of serotonin after treatment with Hypericum extracts, hypericin, carnitine mixture or acetyl L-carnitine, alone or in various combinations, in conjunction with treatment with a substance such as fenfluramine, the neurotoxicity of which manifests itself also through a reduction in brain serotonin concentrations. It is well known, in fact, that fenfluramine [N-ethyl- α -methyl-*m*-(trifluoro-

methyl)phenethylamine] exerts a neurotoxic action on the brain, which is identifiable both histologically on the basis of derangement of the cerebral serotonergic structures and through depletion of serotonin concentrations in the brain.

The tests were conducted using a group of (Sprague-Dawley) male rats which were administered fenfluramine orally at the dose of 5 mg/kg twice daily for 5 days consecutively, either alone or at the same time, and for the same period, as a carnitine mixture (400 mg/kg) (consisting in a combination of L-carnitine + acetyl L-carnitine + propionyl L-carnitine + isovaleryl L-carnitine present in the same weight ratio to one another), or acetyl L-carnitine (400 mg/kg), or Hypericum extract (with a 0.3% hypericin content - 300 mg/kg), or hypericin (1 mg/kg), or various combinations of these products at the same doses.

Two weeks after treatment, the animals were sacrificed and the cerebral cortex isolated and subjected to measurement of the cerebral content both of serotonin (5-HT) and of hydroxy-indole-acetic acid (5-HIAA) according to the method described by Wise (Wise, C.D., Anal. Biochem., 18, 94, 1967) and modified by Ricaurte (Ricaurte, G.A., J. Pharmacol. Exptl. Ther., 261, 616, 1992).

The results obtained in these tests (Table 1) demonstrate that fenfluramine, as a result of its neurotoxic activity, causes substantial lowering of brain concentrations both of 5-HT and 5-HIAA. The reduction in serotonin concentrations is then countered by the administration of Hypericum extract or hypericin, and this effect becomes much more marked, leading almost to abolition of the effect of fenfluramine, when the Hypericum extract or hypericin are combined with the carnitine mixture or with acetyl L-carnitine. Whereas the positive effect of Hypericum extract and of hypericin on serotonin reuptake was well known, no such activity was known for the carnitines, and thus these tests demonstrate a potent synergistic protective effect at the neuronal level and on serotonin concentrations reduced by a neurotoxic substance such as fenfluramine.

Table 1

Concentrations of serotonin (5-HT) and of hydroxy-indole-acetic acid (5-HIAA) in the brain in rats treated with fenfluramine together with a carnitine mixture or with acetyl L-carnitine, Hypericum extract, hypericin, or various combinations of these products

Treatment	Cerebral (cortex) concentrations (ng/mg tissue)	
	5-HT	5-HIAA
CO	0.37 ± 0.018	0.28 ± 0.015
FE	0.17 ± 0.010	0.14 ± 0.011
CC	0.36 ± 0.023	0.30 ± 0.009
AC	0.35 ± 0.020	0.28 ± 0.012
HE	0.38 ± 0.026	0.30 ± 0.029
HYP	0.36 ± 0.019	0.30 ± 0.030
CC + FE	0.20 ± 0.015	0.16 ± 0.009
AC + FE	0.18 ± 0.011	0.15 ± 0.019
HE + FE	0.26 ± 0.023	0.24 ± 0.021
HYP + FE	0.28 ± 0.020	0.25 ± 0.018
CC + HE + FE	0.36 ± 0.029	0.25 ± 0.023
CC + HYP + FE	0.38 ± 0.025	0.29 ± 0.025
AC + HE + FE	0.36 ± 0.024	0.26 ± 0.016
AC + HYP + FE	0.39 ± 0.029	0.28 ± 0.028

CO = controls
FE = fenfluramine
CC = carnitine mixture
AC = acetyl L-carnitine
HE = Hypericum extract
HYP = hypericin

Tests of exploratory activity in mice (Hole Board Test)

It has been proved that in animals, and particularly in the mouse, that small doses of amphetamine can cause a state of anxiety with a corresponding reduction in motor exploration activity. This reduction is not related to sedation caused by the drug in the animal and can be offset using anxiolytic agents.

Using the technique described by Boissier (Boissier J.R., Physiol. Behav., 2, 447, 1967), tests (Hole Board Test) were conducted in order in a group of mice to ascertain whether the reduction in motor

exploration activity induced in the animals by low-dose amphetamine (1 mg/kg i.p.) could be corrected by the oral administration of a carnitine mixture (consisting of a combination of L-carnitine + acetyl L-carnitine + propionyl L-carnitine + isovaleryl L carnitine in the same weight ratio to one another), or of acetyl L-carnitine, or Hypericum extract, or hypericin, or various combinations of these products. As can be seen from the data in Table 2, whereas the administration of carnitines alone had no effect on the exploratory activity of the animals, the administration of Hypericum extracts and of hypericin almost restored exploratory activity to normal, and the combination of carnitines plus Hypericum extract or hypericin increased exploratory activity, to an extent similar to the effect of the higher amphetamine dose.

Table 2

Motor exploration activity in the mouse (Hole Board Test) 30 minutes after administration of amphetamine (1 and 5 mg/kg i.p.) together with carnitine mixture, acetyl L-carnitine, Hypericum extract, hypericin, or various combinations of these products.

Treatment	Variations compared to controls
---	Amphetamine 1 mg/kg -45
---	Amphetamine 5 mg/kg +55
CC	Amphetamine 1 mg/kg -50
AC	Amphetamine 1 mg/kg -48
HE	Amphetamine 1 mg/kg -10
HYP	Amphetamine 1 mg/kg -5
CC + HE	Amphetamine 1 mg/kg +15
CC + HYP	Amphetamine 1 mg/kg +19
AC + HE	Amphetamine 1 mg/kg +25
AC + HYP	Amphetamine 1 mg/kg +20

CC = carnitine mixture 400 mg/kg

AC = acetyl L-carnitine 400 mg/kg

HE = Hypericum extract 300 mg/kg

HYP = hypericin 1 mg/kg

Platform Test

Another behavioural test in the mouse is the Platform Test described by Burnell (Burnell, J.A., J. Comp. Physiol. Psychol., 1, 147, 1965)

which consists in placing the animals on a wooden platform at various heights from the ground and counting the number of animals that do not hesitate to get down from the platform. Ten animals were used per group and the percentage of animals that managed to descend from the platform was calculated. As can be seen from the results in Table 3, whereas none of the control animals descended from the platform at the height of 9 cm from the ground and only approximately 50% descended from the 5-cm platform, the animals' behaviour was modified by the administration of Hypericum extract (300 mg/kg) or hypericin (1 mg/kg). It was modified even more by the administration of a combination of these products plus the carnitine mixture (L-carnitine + acetyl L-carnitine + propionyl L-carnitine + isovaleryl L-carnitine present in the same weight ratio to one another, making a total dose of 400 mg/kg) or acetyl L-carnitine 400 mg/kg, neither of which modifies the animals' behaviour when administered alone.

The results of these tests also clearly show a distinct potentiation of the action of Hypericum extract (300 mg/kg) and hypericin (1 mg/kg) as a result of combination with carnitines.

Table 3
Platform Test in mice

Treatment	% of mice descending from	
	9 cm	5 cm
Controls	0	60
Carnitine mixture, 400 mg/kg	0	70
Acetyl L-carnitine, 400 mg/kg	0	70
Hypericum extract, 300 mg/kg	20	90
Hypericin, 1 mg/kg	30	90
Carnitine mixture, 400 mg/kg + Hypericum extract, 300 mg/kg	70	100
Carnitine mixture, 400 mg/kg + hypericin, 1 mg/kg	60	100
Acetyl L-carnitine, 400 mg/kg + Hypericum extract, 300 mg/kg	60	100
Acetyl L-carnitine, 400 mg/kg + hypericin, 1 mg/kg	80	100

Tests of immobility induced by forced swimming

One of the tests regarded as being most significant for assessing the activity of antidepressant substances is the forced swimming test in the mouse, which measures the changes in swimming-induced immobility which the various test substances produce (Borsini, F., Psychopharmacology, 94, 147, 1988). In these tests, the technique described by Persolt was adopted (Persolt, R.D., Eur. J. Pharmacol., 57, 201, 1979 - Persolt, R.D., Arch. Int. Pharmacology, 229, 327, 1977) using ten rats per group. The animals were placed in beakers measuring 14 cm in height and approximately 12 cm in internal diameter which were filled with water (20-22°C) up to 7.5 cm from the rim and then left there for six minutes. The duration of the immobility was calculated during the last four minutes. The mice were considered immobile when they performed only the movements necessary to keep themselves afloat on the water:

The substances tested were administered orally in two administrations six hours and three hours prior to the start of the experiment.

As apparent from the results in Table 4, the period of immobility was reduced by the administration of Hypericum extract and hypericin, but the reduction was much more marked when Hypericum extract or hypericin were combined with the administration of the carnitine mixture (combination of L-carnitine + acetyl L-carnitine + propionyl L-carnitine + isovaleryl L-carnitine present in the same weight ratio to one another) or with acetyl L-carnitine, which, when administered alone, had no reducing effect on immobility time.

Table 4

Tests of immobility time induced by forced swimming in mice

Treatment	Immobility time
Controls	210 ± 8
Carnitine mixture	220 ± 7
Acetyl L-carnitine	204 ± 8
Hypericum extract	190 ± 9
Hypericin	195 ± 5
Carnitine mixture + Hypericum extract	170 ± 6
Carnitine mixture + hypericin	165 ± 4
Acetyl L-carnitine + Hypericum mixture	178 ± 9
Acetyl L-carnitine + hypericin	172 ± 7

Isolation-induced aggression tests

The method adopted for these tests was the Scott method (Scott, J.P., *Physiol. Zool.*, 24, 273, 1951) as modified by Sanchez (Sanchez, C., *Psychopharmacology*, 110, 53, 1993). This method consists in making the mice aggressive by keeping them isolated for twenty-one days in a cage and in assessing, after treatment, the latency time needed to trigger the aggression of the isolated animal when another animal is put in the cage with it. Only animals with latency times of less than 10 seconds before attacking were included in the tests, and the time of attack was taken as the time the isolated animal bit or tried to bite the other animal introduced into the cage.

The observation time was 180 seconds and the experiment was started 30 minutes after administration of the products tested. All isolated animals were treated, both eight hours and half an hour before the test, with carnitine mixture (consisting of a combination of L-carnitine + acetyl L-carnitine + propionyl L-carnitine + isovaleryl L-carnitine in an equiponderal ratio to one another) (400 mg/kg), or with acetyl L-carnitine (400 mg/kg) or with Hypericum extract (300 mg/kg) or with hypericin (1 mg/kg), or with various combinations of these products.

The results of these tests (Table 5) demonstrate that, whereas carnitines alone do not modify aggression latency times in mice treated with them, their use in combination with either Hypericum extract or hypericin potentiates to a highly significant extent the reduction in aggression which the latter produce in mice.

These tests, too, demonstrate that an unexpected, sudden synergistic effect occurs between carnitines and Hypericum extract or hypericin.

Table 5

Isolation-induced aggression tests. Latency time of attack in male mice treated with carnitine mixture, acetyl L-carnitine, Hypericum extract, hypericin, or various combinations of these products.

Treatment	Latency time in seconds
Controls	8 ± 2
Carnitine mixture, 400 mg/kg	11 ± 1
Acetyl L-carnitine, 400 mg/kg	14 ± 3
Hypericum extract, 300 mg/kg	80 ± 10
Hypericin, 1 mg/kg	100 ± 9
Carnitine mixture, 400 mg/kg + Hypericum extract, 300 mg/kg	140 ± 12
Carnitine mixture, 400 mg/kg + hypericin, 1 mg/kg	150 ± 6
Acetyl L-carnitine, 400 mg/kg + Hypericum extract, 300 mg/kg	150 ± 9
Acetyl L-carnitine, 400 mg/kg + hypericin, 1 mg/kg	160 ± 11

Illustrative, non-limiting examples of formulations according to the invention are reported hereinbelow.

1)	Carnitine mixture (L-carnitine mg 150, acetyl L-carnitine mg 150, propionyl L-carnitine mg 150, isovaleryl L-carnitine mg 150)	mg	600
	Hypericum extract (titled 0.3% of Hypericin)	mg	600
2)	Carnitine mixture (L-carnitine mg 150, acetyl L-carnitine mg 150, propionyl L-carnitine mg 150, isovaleryl L-carnitine mg 150)	mg	600
	Hypericin	mg	2

3)	Acetyl L-carnitine	mg	600
	Hypericum extract (titled 0.3% of Hypericin)	mg	600
4)	Acetyl L-carnitine	mg	600
	Hypericin	mg	2
5)	Carnitine mixture (L-carnitine mg 75, acetyl L-carnitine mg 75, propionyl L-carnitine mg 75, isovaleryl L-carnitine mg 75)	mg	300
	Hypericum extract (titled 0.3% of Hypericin)	mg	300
6)	Carnitine mixture (L-carnitine mg 75, acetyl L-carnitine mg 75, propionyl L-carnitine mg 75, isovaleryl L-carnitine mg 75)	mg	300
	Hypericin	mg	1
7)	Acetyl L-carnitine	mg	300
	Hypericum extract (titled 0.3% of Hypericin)	mg	300
8)	Acetyl L-carnitine	mg	300
	Hypericin	mg	1
9)	Carnitine mixture (L-carnitine mg 75, acetyl L-carnitine mg 75, propionyl L-carnitine mg 75, isovaleryl L-carnitine mg 75)	mg	300
	Hypericum extract (titled 0.3% of Hypericin)	mg	300
	L-tyrosine	mg	50
	Histidine	mg	50
	Taurine	mg	50
	Glutamine	mg	50
	Valine	mg	50
	Tryptophan	mg	50

10)	Carnitine mixture (L-carnitine mg 75, acetyl L-carnitine mg 75, propionyl L-carnitine mg 75, isovaleryl L-carnitine mg 75)	mg	300
	Hypericum extract (titled 0.3% of Hypericin)	mg	300
	Phosphoserine	mg	100
	Glyceryl phosphorylcholine	mg	100
	Tryptophan	mg	100
	Tyrosine	mg	100
	CoQ10	mg	10
	Selenium	mg	10

What is meant by pharmacologically acceptable salt of L-carnitine or alkanoyl L-carnitine is any salt of these active ingredients with an acid that does not give rise to unwanted toxic or side effects. These acids are well known to pharmacy experts.

Non-limiting examples of suitable salts are the following: chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate; acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, acid maleate; orotate; oxalate, acid oxalate; sulphate, acid sulphate, trichloroacetate, trifluoroacetate and methane sulphonate.

A list of FDA-approved pharmacologically acceptable salts is given in Int. J. of Pharm. 33, (1986), 201-217; this latter publication is incorporated herein by reference.

The compositon according to the invention may also comprise vitamins, coenzymes, minerals substances and antioxidants.

Appropriate excipients to be used to prepare the compositions having regards to the specific route of administration, will be apparent to the pharmacy and food industry experts.

Claims

1. A composition which comprises:
 - (a) acetyl L-carnitine or a pharmacologically acceptable salt thereof; and
 - (b) hypericin or *Hypericum extract* (*Hypericum perforatum* L.) comprising at least 0.3% by weight of hypericin.
2. The composition of claim 1, wherein the ingredient (a) further comprises a "carnitine" selected from the group comprising L-carnitine, propionyl L-carnitine, valeryl L-carnitine, isovaleryl L-carnitine or their pharmacologically acceptable salts or mixtures thereof.
3. The composition of claim 1 or 2 wherein the weight ratio (a):(b) is from 1:0.01 to 1:1.
4. The composition of any of the preceding claims, wherein the ingredient (b) is in the form of vegetal extracts which contain the ingredient itself.
5. The composition of claim 4, wherein said vegetal extracts comprise flowers, terminal buds or leaves of *Hypericum* plants.
6. The composition of any of the preceding claims wherein the pharmacologically acceptable salt of L-carnitine or alkanoyl L-carnitine is selected from the group comprising: chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate, acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, acid maleate; orotate; acid oxalate; sulphate, acid sulphate; trichloroacetate; trifluoroacetate and methane sulphonate.
7. The composition of any of the preceding claims, which further comprises vitamins, coenzymes, mineral substances and antioxidants.

8. The composition of any of the preceding claims, orally administrable in the form of a dietary supplement.
9. The composition of any of the preceding claims, orally, parenterally, rectally or transdermally administrable in the form of a medicament.
10. The dietary supplement of claim 8, for the prevention of nervous alterations due to anxiety states, irritability or depression.
11. The medicament of claim 9, for the therapeutic treatment of nervous alterations due to anxiety states, irritability or depression.
12. The dietary supplement of claim 8 or 10, in a solid, semi-solid or liquid form.
13. The medicament of claim 9 or 11, in a solid, semi-solid or liquid form.
14. The dietary supplement of claim 12, in the form of pills, tablets, capsules, granulates or syrup.
15. The medicament of claim 13, in the form of pills, tablets, capsules, granulates, syrup, vials or drops.